Coherus Oncology (CHRS) Asset Utilization Ratio (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Asset Utilization Ratio data on file, last reported at 0.18 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio rose 131.31% year-over-year to 0.18; the trailing twelve-month figure through Mar 2026 stood at 0.18 (up 131.31% YoY), and the FY2025 full-year result was 0.12, up 143.74% from the prior year.
• Asset Utilization Ratio climbed to 0.18 in Q1 2026, from 0.11 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.48 in Q2 2022 to a low of 0.06 in Q4 2024.
• A 5-year average of 0.28 and a median of 0.33 in 2024 frame the typical range for Asset Utilization Ratio.
• Across the five-year window, Asset Utilization Ratio sank 86.95% in 2024 and surged 131.31% in 2026, its largest moves.
• Tracing CHRS's Asset Utilization Ratio over 5 years: stood at 0.41 in 2022, then climbed by 3.65% to 0.42 in 2023, then slumped by 86.95% to 0.06 in 2024, then surged by 96.66% to 0.11 in 2025, then soared by 64.28% to 0.18 in 2026.
• Business Quant data shows CHRS's Asset Utilization Ratio at 0.18 in Q1 2026, 0.11 in Q4 2025, and 0.08 in Q3 2025.